The Efficacy of (Neo)Adjuvant Capecitabine-Containing Regimens in High-Risk Breast Cancer


The Efficacy of (Neo)Adjuvant Capecitabine-Containing Regimens in High-Risk Breast Cancer
Slides from presentations at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)
Lindman H et al. Integration of capecitabine into anthracycline- and taxane-based adjuvant therapy for triple-negative early breast cancer: Final subgroup analysis of the FinXX study. San Antonio Breast Cancer Symposium 2010;Abstract PD01-02.

Steger GG et al. Review of capecitabine for the treatment of triple-negative early breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract PD01-03.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.